Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
33 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03566732 | ERANet-LAC CODE: International Care Of the Dying Evaluation | completed | — | 914 | University of BergenOTHER | 7 | Sep 11, 2026 | clinicaltrials |
| NCT05879926 | Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25(OFSET) | recruiting | Phase 3 | 3,960 | NRG OncologyOTHER | 8 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT05328765 | A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection(ACTION HIV) | completed | — | 369 | Latin American Cooperative Oncology GroupOTHER | 5 | Aug 28, 2026 | clinicaltrials |
| NCT04158258 | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | completed | — | 2,907 | Hoffmann-La RocheINDUSTRY | 10 | Aug 17, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials GroupNETWORK | 4 | Jul 14, 2026 | clinicaltrials |
| NCT04871542 | Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | recruiting | — | 2,062 | SWOG Cancer Research NetworkNETWORK | 5 | May 5, 2026 | clinicaltrials |
| NCT06205953 | A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)(EUREKA) | recruiting | — | 400 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 6 | Apr 16, 2026 | clinicaltrials |
| NCT04294927 | TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention(TUBA-WISP-II) | recruiting | N/A | 3,000 | University Medical Center NijmegenOTHER | 16 | Apr 6, 2026 | clinicaltrials |
| NCT05040360 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 141 | SWOG Cancer Research NetworkNETWORK | 3 | Dec 15, 2025 | clinicaltrials |
| NCT05000697 | Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait(CCHOWW) | recruiting | N/A | 216 | Hospital Alemão Oswaldo CruzOTHER | 3 | Nov 27, 2024 | clinicaltrials |
| NCT01881659 | Cervical Cancer Screening With Human Papillomavirus Testing(ESTAMPA) | unknown | — | 50,000 | International Agency for Research on CancerOTHER | 9 | Mar 14, 2023 | clinicaltrials |
| NCT01760356 | Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients(3PIGREF) | terminated | — | 141 | UDA Centro Nacional Hepato-Bilio-PancreáticoOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT03725475 | A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients(KINDLE) | completed | — | 3,111 | AstraZenecaINDUSTRY | 10 | Oct 5, 2020 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT02326857 | Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment | completed | — | 1,334 | National Cancer Institute (NCI)NIH | 5 | Sep 25, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT02765503 | Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial(HYPNO) | unknown | N/A | 836 | International Atomic Energy AgencyOTHER_GOV | 9 | Aug 8, 2019 | clinicaltrials |
| NCT01142674 | T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma | completed | — | 1,650 | Associazione Angela Serra per la ricerca sul cancroOTHER | 14 | Jul 8, 2019 | clinicaltrials |
| NCT03721289 | Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients(PANORAMRETRO) | completed | — | 463 | AstraZenecaINDUSTRY | 4 | Jun 12, 2019 | clinicaltrials |
| NCT02535026 | An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants | completed | — | 580 | Hoffmann-La RocheINDUSTRY | 2 | Apr 10, 2017 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT02563054 | A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer | completed | Phase 3 | 316 | Hoffmann-La RocheINDUSTRY | 14 | Nov 2, 2016 | clinicaltrials |
| NCT00812175 | Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib(GIDEON) | completed | — | 3,371 | BayerINDUSTRY | 39 | Oct 17, 2016 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00391092 | A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 3 | 424 | Hoffmann-La RocheINDUSTRY | 16 | Aug 28, 2015 | clinicaltrials |
| NCT00408278 | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | completed | Phase 4 | 300 | PETHEMA FoundationOTHER | 3 | Oct 28, 2014 | clinicaltrials |
| NCT00312208 | Docetaxel in Breast Cancer | completed | Phase 3 | 3,299 | SanofiINDUSTRY | 37 | Dec 30, 2013 | clinicaltrials |
| NCT00262067 | A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) | unknown | Phase 3 | 1,237 | Genentech, Inc.INDUSTRY | 22 | Dec 13, 2013 | clinicaltrials |
| NCT00485979 | Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients(SATIN) | completed | Phase 2 | 330 | SanofiINDUSTRY | 8 | Jun 28, 2011 | clinicaltrials |
| NCT00688740 | Docetaxel in Node Positive Adjuvant Breast Cancer(TAX316) | completed | Phase 3 | 1,491 | SanofiINDUSTRY | 20 | Feb 16, 2011 | clinicaltrials |
| NCT00401323 | Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 568 | SanofiINDUSTRY | 20 | Jan 20, 2011 | clinicaltrials |
Data updated 18 days agoSource updated unknownsource: clinicaltrials